Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that ...
BioSpace1d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
Pharmabiz1d
Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...
Eli Lilly announces one-year histologic mirikizumab data
Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...
Johnson & Johnson Earnings: Both Segments See Solid Q3 Growth
The firm reported growth slightly ahead of our expectations.
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
FiercePharma2d
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
Hims & Hers up 10% as FDA reconsiders taking Lilly weight loss drug off shortage list
Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's ...
Eli Lilly and Company: Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...
Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease
(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.
Medindia2d
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab INDIANAPOLIS, Oct. /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data ...